Harrow
HROW
30.41
-1.72
-5.35%
Harrow
US · HROW
#3155 by market cap
30.41
-1.72
-5.35%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 8 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.3 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 60.71% +2.27pp
- Institutions
- 256 -8
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund42.33%
Individual/Insider16.41%
Hedge Fund12.08%
VC/PE Fund3.00%
Private Company1.23%
Public Company1.21%
Government Pension Fund0.55%
Insurance Company0.22%
Family Office/Trust0.10%
Other22.88%
Top holders as of 2026-05-14
Mark Baum
7.98% · 3.00M sh
BlackRock
7.88% · 2.96M sh
Opaleye Management Inc.
5.61% · 2.11M sh
Daniel Kaufman
5.00% · 1.88M sh
Private Capital Management, LLC
4.26% · 1.60M sh
Vanguard Capital Management, LLC
3.72% · 1.39M sh
State Street Global Advisors
2.73% · 1.02M sh
Deep Track Capital, LP
2.58% · 969.00K sh
Geode Capital Management, LLC
2.27% · 852.94K sh
Andrew Boll
2.17% · 814.68K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Mark Baum | CEO, Chairman of the Board & Founder | 7.98% |
| Andrew Boll | President, CFO & Chief Accounting Officer | 2.17% |
| John Saharek | Former President & CEO of Harrow’s ImprimisRx Division | 1.25% |
| Adrienne Graves | Independent Director | 0.00% |
| Lauren Silvernail | Independent Director | 0.00% |
| Opaleye Management Inc. | -- | -- |
| Amir Shojaei | Chief Scientific Officer | -- |
| Perry Sternberg | Lead Independent Director | -- |
| Randall Pollard | Former Chief Accounting Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-13 | Amir Shojaei | Chief Scientific Officer | Derivative Exercise and Sale | -11,250 | $35.96–40.00 |
| 2026-06-17 | Adrienne Graves | Independent Director | Other Derivative Acquisition | +5,248 | -- |
| 2026-06-17 | Lauren Silvernail | Independent Director | Other Derivative Acquisition | +5,248 | -- |
| 2026-06-17 | Perry Sternberg | Lead Independent Director | Other Derivative Acquisition | +5,248 | -- |
| 2026-05-17 | Adrienne Graves | Independent Director | Open Market Acquisition | +1,000 | $31.07 |
| 2026-05-17 | Lauren Silvernail | Independent Director | Open Market Acquisition | +1,000 | $31.00 |
| 2026-05-14 | Amir Shojaei | Chief Scientific Officer | Other Derivative Acquisition | +10,000 | -- |
| 2026-05-13 | Mark Baum | CEO, Chairman of the Board & Founder | Open Market Acquisition | +10,000 | $30.20 |
| 2026-05-13 | Andrew Boll | President, CFO & Chief Accounting Officer | Open Market Acquisition | +3,500 | $29.90 |
| 2026-03-03 | Opaleye Management Inc. | -- | Open Market Disposition | -198,572 | $39.15–39.67 |
| 2026-02-26 | Opaleye Management Inc. | -- | Open Market Disposition | -5,000 | $54.18 |
| 2026-01-05 | Opaleye Management Inc. | -- | Open Market Disposition | -20,000 | $53.35 |
| 2025-12-11 | Mark Baum | CEO, Chairman of the Board & Founder | Derivative Exercise and Sale | -79,994 | $3.95–47.06 |
| 2025-12-11 | Mark Baum | CEO, Chairman of the Board & Founder | Derivative Exercise and Retained | +100,006 | $3.95 |
| 2025-12-11 | Andrew Boll | President, CFO & Chief Accounting Officer | Derivative Exercise and Sale | -26,665 | $3.95–47.06 |
| 2025-12-11 | Andrew Boll | President, CFO & Chief Accounting Officer | Derivative Exercise and Retained | +33,335 | $3.95 |
| 2025-08-31 | Randall Pollard | Former Chief Accounting Officer | Other Derivative Acquisition | +30,000 | $39.00 |
| 2025-07-20 | Mark Baum | CEO, Chairman of the Board & Founder | Derivative Exercise and Sale | -313,338 | $7.87–37.08 |
| 2025-07-20 | Mark Baum | CEO, Chairman of the Board & Founder | Derivative Exercise and Retained | +286,662 | $7.87 |
| 2025-06-30 | Mark Baum | CEO, Chairman of the Board & Founder | Other Derivative Acquisition | +889,500 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Harrow discussion 0 comments